Multicenter, Real-World Study in Patients with R/R Large B-Cell Lymphoma (LBCL) Who Received Lisocabtagene Maraleucel (liso-cel) in the United States (US)Jennifer L. Crombie, Marcelo C. Pasquini, Loretta J. Nastoupil et al.|Blood|2023Cited by 17
A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphomaReid W. Merryman, Caron A. Jacobson, David C. Fisher et al.|Annals of Hematology|2023Cited by 7
Multicenter, Real-World Study in Patients with R/R Large B-Cell Lymphoma (LBCL) Who Received Lisocabtagene Maraleucel (liso-cel) in the United States (US)M. Lia Palomba, Marcelo C. Pasquini, Jennifer L. Crombie et al.|Transplantation and Cellular Therapy|2024Cited by 7
CRS or ICANS Are Rare Beyond 2 Weeks After Lisocabtagene Maraleucel Infusion: Data From Clinical Trials and the Real-World SettingBradley D. Hunter, Manali Kamdar, Matthew A. Lunning et al.|Transplantation and Cellular Therapy|2025Cited by 3
Dual Immune Checkpoint Agents in Combination with Rituximab for Patients with Relapsed or Refractory Follicular LymphomaReid W. Merryman, Caron A. Jacobson, Robert Redd et al.|Blood|2022Cited by 1